Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Exclusion Criteria

• •Inability to comply with study and/or follow-up procedures
• •Current or recent (within 4 weeks of the first infusion of this study) participation in another experimental drug study.
• •Active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within last five years
• •Patients must have undergone standard cytoreductive surgery as part of primary treatment to be eligible for this study and therefore are not of childbearing potential.Nursing mothers are excluded.
• •Inadequately controlled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \> 90 mmHg)
• •Prior history of hypertensive crisis or hypertensive encephalopathy
• •New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix C)
• •History of myocardial infarction or unstable angina within 6 months prior to Day 1
• •History of stroke or transient ischemic attack within 6 months prior to Day 1
• •Known CNS disease, except for treated brain metastasis
• •Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded
• •Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1
• •History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
• •Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) or tumor involving major vessels.
• •Major surgical procedure such as laparotomy, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study
• •Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
• •History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day
• •Patients with clinical symptoms or signs of GI obstruction who require parenteral hydration, parenteral nutrition, or tube feeding
• •Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure
• •Serious, non-healing wound, active ulcer, or untreated bone fracture
• •Known hypersensitivity to any component of bevacizumab
• •Allergy to seafood
• •Active autoimmune disease (i.e. rheumatoid arthritis, ulcerative colitis etc); or immune deficiency (HIV, hypogammaglobulinemia); or known active infections with Hepatitis B or Hepatitis C; or those receiving immunosuppressive drugs (such as chronic systemic corticosteroids or cyclosporin, etc); or those receiving chronic antiinflammatory drugs (intermittent use of anti-inflammatory drugs is permitted).